News archive
- April 2022
- March 2022
- February 2022
- January 2022
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- October 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- December 2019
- November 2019
- October 2019
- August 2019
- July 2019
- June 2019
- April 2019
- February 2019
- January 2019
- November 2018
- October 2018
- September 2018
- June 2018
- May 2018
- April 2018
- February 2018
- December 2017
- August 2017
- June 2017
- November 2016
- October 2016
- June 2016
- December 2015
- April 2015
- January 2015
Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with ischemic stroke
31.03.2021
Stroke is still the most significant problem of the modern medicine and the leading cause of mortality and morbidity.
The efficacy of ethylmethylhydroxypyridine succinate in patients with cerebrovascular pathology complicated with diabetes mellitus and metabolic syndrome
17.03.2021
Arterial hypertension, diabetes mellitus, obesity and dyslipidemia continue to be the main risk factors for diseases of the circulatory system and the leading causes of mortality in the world, the combination of these diseases significantly increases the likelihood of the development and more rapid progression of cardiovascular and cerebrovascular pathology.
Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia
09.03.2021
Objective. To study of efficacy and safety of mexidol used as intravenous infusion for 14 days, followed by per os treatment with mexidol FORTE 250 for 60 days in patients with chronic brain ischemia (CHM) complicated with arterial hypertension and atherosclerosis.